Macrogenics (MGNX) Cost of Revenue (2021 - 2024)
Macrogenics' (MGNX) quarterly Cost of Revenue came in at $233000.0 in Q4 2024, up 42.94% year-on-year from $163000.0 in Q1 2024, and up 38.69% on a QoQ basis from $168000.0 in Q3 2024.
Macrogenics (MGNX) Cost of Revenue (2021 - 2024) Analysis & Trends
Macrogenics (MGNX) has 4 years of Cost of Revenue data on file, last reported at $233000.0 in Q4 2024.
- On a quarterly basis, Cost of Revenue rose 42.94% year-over-year to $233000.0 in Q4 2024; TTM through Sep 2025 was $233000.0, a 70.01% decrease from a year earlier, with the FY2024 full-year figure at $847000.0, up 36.83% from the prior year.
- Cost of Revenue for Q4 2024 stood at $233000.0, up from $168000.0 in the prior quarter.
- Over the last five years, Cost of Revenue for MGNX reached as high as $3.0 million in Q3 2022 and fell as low as $17000.0 in Q1 2021.
- Historically, Cost of Revenue has averaged $466750.0 across 4 years, with a median of $172000.0 in 2024.
- Across the five-year window, Cost of Revenue jumped 718.18% in 2022 and plunged 97.17% in 2023, its largest moves.
- Year by year, Cost of Revenue stood at $947000.0 in 2021, then tumbled by 87.75% to $116000.0 in 2022, then surged by 40.52% to $163000.0 in 2023, then jumped by 42.94% to $233000.0 in 2024.
- Per Business Quant data, the three most recent Cost of Revenue figures were $233000.0 in Q4 2024, $168000.0 in Q3 2024, and $176000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Macrogenics | 255.39 Mn | 188.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 233,000.00 |
| Dec 31, 2024 | 233,000.00 |
| Sep 30, 2024 | 168,000.00 |
| Sep 30, 2024 | 168,000.00 |
| Jun 30, 2024 | 176,000.00 |
| Jun 30, 2024 | 176,000.00 |
| Mar 31, 2024 | 270,000.00 |
| Mar 31, 2024 | 270,000.00 |
| Dec 31, 2023 | 163,000.00 |
| Dec 31, 2023 | 163,000.00 |
| Sep 30, 2023 | 85,000.00 |
| Sep 30, 2023 | 85,000.00 |
| Jun 30, 2023 | 258,000.00 |
| Jun 30, 2023 | 258,000.00 |
| Mar 31, 2023 | 113,000.00 |
| Mar 31, 2023 | 113,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Sep 30, 2022 | 3.01 Mn |
| Sep 30, 2022 | 3.01 Mn |